Reuters logo
BRIEF-RedHill Biopharma accelerates RHB-104 Phase III study in Crohn’s Disease
October 2, 2017 / 11:15 AM / 3 months ago

BRIEF-RedHill Biopharma accelerates RHB-104 Phase III study in Crohn’s Disease

Oct 2 (Reuters) - Redhill Biopharma Ltd

* RedHill Biopharma Ltd - ‍development program will be shortened by approximately one year​

* RedHill Biopharma Ltd - ‍enrollment expected to be completed by November 2017 and top-line results expected in mid-2018​

* RedHill Biopharma Ltd - ‍estimated cost saving is approximately $14 million​

* RedHill Biopharma - curtailed target sample size in ongoing first Phase III study with RHB-104 for Crohn’s Disease from 410 to about 325 subjects​

* RedHill Biopharma Ltd - ‍accelerates RHB-104 phase III study in Crohn’s Disease with top-line results expected mid-2018​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below